Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Motor impairments at presentation of clinically isolated syndrome suggestive of multiple sclerosis: Characterization of different disease subtypes.
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.
Receptos begins enrollment of Phase 3 trial of RPC1063 in relapsing multiple sclerosis
Ampyra (dalfampridine) medication guide
Assessment of cerebral venous return by a novel plethysmography method.
Sleep Disorders and Multiple Sclerosis: A Clinical and Polysomnography Study.
Exercise and quality of life in women with multiple sclerosis.
Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice.
Psoriasis during natalizumab treatment for multiple sclerosis.
A gender-related action of IFNbeta-therapy was found in multiple sclerosis.
Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.
Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program.
MS and NMO: Partners No More.
Oligodendrocytes and the early multiple sclerosis lesion.
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Improving Hand Functional Use in Subjects with Multiple Sclerosis Using a Musical Keyboard: A Randomized Controlled Trial.
Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial.
Severe haematological complications during treatment with natalizumab.
Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study.
1,25-Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis.
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.
Age-dependent effects on the treatment response of natalizumab in MS patients.
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis.
Momenta Pharmaceuticals Announces CAFC Decision to Invalidate Remanded Teva Pharmaceuticals Patent in Daily COPAXONE(R) 20 mg Suit
CHMP recommends granting a marketing authorization for Santhera's Raxone® for the treatment of Leber's Hereditary Optic Neuropathy (LHON)

Pages